Harvard Bioscience, Inc. HBIO
9.39 USD +0.30 (+3.30%)
Nov 10, 2026, 3:59 PM EST
8.21 Day range 9.60
4.00 52-week range 9.60
- YTD
- +40.15%
- 1 year
- +61.90%
News
seekingalpha.com Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript Harvard Bioscience, Inc. (HBIO) Q3 2026 Earnings Call Transcript
benzinga.com Harvard Bioscience Q3 2026 Earnings Call Transcript Harvard Bioscience (NASDAQ:HBIO) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Harvard Bioscience Raises FY2026 Sales Guidance from $88.281M-$90.012M to $89.147M-$90.877M vs $89.794M Est Harvard Bioscience (NASDAQ:HBIO) raises FY2026 sales outlook from $88.281 million-$90.012 million to $89.147 million-$90.877 million vs $89.794 million estimate.
benzinga.com Harvard Bioscience Sees Q4 Sales $23.700M-$25.500M vs $24.500M Est Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $23.700 million-$25.500 million vs $24.500 million analyst estimate.
globenewswire.com Harvard Bioscience Announces Third Quarter 2026 Financial Results Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial…
benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
benzinga.com Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est. Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.
benzinga.com Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.- benzinga.com Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of…
benzinga.com Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026 On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial…
benzinga.com Harvard Bioscience Q1 2026 Earnings Call Transcript 
benzinga.com Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
benzinga.com Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.- benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
benzinga.com Harvard Bioscience Sees Q1 Sales $20.000M-$22.000M vs $21.250M Est Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million analyst estimate.- benzinga.com Harvard Bioscience Q4 Sales $23.735M Beat $23.100M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $23.735 million which beat the analyst consensus estimate of $23.100 million by 2.75 percent. This is a 3.34 percent decrease over sales…
- benzinga.com Earnings Scheduled For March 12, 2026
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Harvard Bioscience Board Approves 1-For-10 Reverse Stock Split, Effective March 13 Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.…
- benzinga.com Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter…
benzinga.com Harvard Bioscience Trims Footprint To Run Leaner, Faster, And Cheaper Harvard Bioscience restructures production, closing MA plant, shifting output to US and abroad. Savings expected, costs until 2027.- benzinga.com Harvard Bioscience Strikes Agreement With BroadOak Capital Partners To Offer $40M Credit Facility Of Three Term Loans Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), today announced it entered into an agreement with BroadOak Capital Partners (collectively, "BroadOak"), a…
- benzinga.com Harvard Bioscience Sees Q4 Sales $22.500M-$24.500M vs $23.100M Est Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $22.500 million-$24.500 million vs $23.100 million analyst estimate.
- benzinga.com Harvard Bioscience Q3 Sales $20.591M Beat $20.000M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.000 million by 2.96 percent. This is a 6.28 percent decrease over sales…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2 Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.
- benzinga.com Harvard Bioscience Enters Sixth Amendment To Credit Agreement; Lenders Agree Not To Test Financial Covenants For Q3 2025; Agrees To Pay $400K Fees To Lenders; Explores Alternative Capital Sources For Refinancing; Says There Is Substantial Doubt About Co's Ability To Continue As A Going Concern Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") entered into a Sixth Amendment (the "Sixth Amendment") to the Credit Agreement,…
- benzinga.com Harvard Bioscience Sees Q3 Sales $19.000M-$21.000M vs $21.75M Est Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $19.000 million-$21.000 million vs $21.75 million analyst estimate.
- benzinga.com Harvard Bioscience Q2 Adj. EPS $(0.01), Inline, Sales $20.45M Beat $20.40M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $20.45 million which beat the analyst…
- benzinga.com Earnings Scheduled For August 11, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3 Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Harvard Bioscience Sees Q2 Sales $18.000M-$20.000M vs $19.20M Est Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $18.000 million-$20.000 million vs $19.20 million analyst estimate.
- benzinga.com Harvard Bioscience Q1 Adj. EPS $(0.01) Beats $(0.04) Estimate, Sales $21.77M Beat $19.20M Estimate Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 150 percent decrease over earnings of…